The case for & against
Bull & Bear analysis
Cardiff Oncology, Inc. (NASDAQ: CRDF) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer, particularly those targeting RAS mutations in metastatic colorectal cancer (MCRC). The company is advancing its lead product, Onvansertib, in clinical trials to transform treatment paradigms amidst the pressing need for effective therapies in a landscape where no new options have been approved for nearly two decades. Cardiff aims to leverage its strategic partnership with Pfizer Ignite to enhance trial operations and capitalize on computational advances in oncology therapeutics.
Bull says
- ↑Onvansertib achieved 64% ORR vs 33% control in CARTF004 trial
- ↑Pfizer Ignite partnership enhances trial execution efficiency
- ↑Exploring ovarian and pancreatic indications with positive preclinical data
- ↑$91.7M cash and short-term investments fund operations into 2027
- ↑Book-to-Price of 0.55 suggests potential undervaluation
- ↑First-in-class RAS-mutated MCRC therapy addresses unmet need
Bear says
- ↓Negative profitability profile with weak margins and earnings yield
- ↓Short interest at 1.66 indicates market skepticism and price swings
- ↓Q4 2024 cash burn of $10.3M heightens depletion risk
- ↓FDA delays or adverse feedback could derail trial milestones
- ↓Competitors like Amgen and Regeneron may introduce superior RAS therapies
- ↓Downward earnings revisions reflect softening growth expectations
Investment themes with CRDF
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q3 2023 · Mgmt. Guidance
Transcript signals
Bull points
- Yes, we remain very bullish in being able to put out the first interim data or preliminary data from the trial.
- strong new data from our lead program in K-RAS mutated metastatic colorectal cancer, the conclusions from a highly supportive meeting with the FDA, and an expansion of our relationship with Pfizer.
- our drug, Onvansertib, has shown clear signals of efficacy and tolerability in combination with chemotherapies and as a single agent in our clinical trials across multiple indications.